Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Featured Jobs

Associate Director, Global Production Planning & Inventory Control Job
Celgene Corporation - Basking Ridge, NJ, US
Clinical Research Coordinator
Lovelace Respiratory Research Institute - Albuquerque, NM
Scientist/Sr. Scientist, Bio-analytical Chemistry
Dicerna Pharmaceuticals, Inc. - Watertown, MA
Director, IT Global Operation Services, End-User Informatics Job
Celgene Corporation - Summit, NJ, US
Hematology Oncology Consultant, Hematology - Louisiana North Job
Celgene Corporation - Louisiana, LA, US

More Jobs >>

Events

Biomarker Applications for Improved Clinical Trial Outcomes
Nov. 15-16 — Boston
CHI's Summit for Clinical Ops Executives (Scope)
February 7-9 — Miami
New Paradigms to Fund & Move Biotech
January 11-12, 2012 — San Francisco, CA
Life Science in the Cloud
Nov 16, 2011 — Cambridge, MA

More Events >>

Related Tags >> Biovest cancer vaccine non-Hodgkin's lymphoma Hawaii Biotech

BiovaxID News

Most Popular BiovaxID Story

Lymphoma vaccine extends survival in late-stage study

June 2, 2011 — 7:15am ET | By Maureen Martino

In a study published in the online version of the Journal of Clinical Oncology, researchers at the University of Texas MD Anderson Cancer Center say a Phase III trial of the therapeutic vaccine Read more...

BiovaxID Press Releases

Biovest to Present on Regulatory Strategy for BiovaxID® Cancer Vaccine at MD Becker Cancer Immunotherapy Conference
Biovest Reports New BiovaxID® Cancer Vaccine Manufacturing Site Has Been Completed at its Minnesota Cell Culture Center
Cancer Vaccines Poised to Reach $3 Billion in Sales by 2015
Biovest to Present at ROTH Capital OC Growth Stock Conference
New Phase III Data Analysis for BiovaxID®, Personalized Lymphoma Vaccine, to Be Presented at ASH Annual Meeting

Latest Headlines

Lymphoma vaccine extends survival in late-stage study
June 2, 2011
Biovest sees new opportunities following bankruptcy
April 6, 2011
BiovaxID gets EMA orphan status
March 9, 2011
Biovest wins orphan drug status for cancer vax
July 29, 2010

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK